• Optimized GBA1-mRNA Restores Lysosomal GCase in Gaucher Dise

  2026-07-03

  A recent study demonstrates that rational engineering of human GBA1-mRNA enables robust, sustained expression of functional glucocerebrosidase (GCase) in cellular and animal models of Gaucher disease. This innovation supports mRNA-based therapeutics as a promising alternative to enzyme replacement, with substantial implications for lysosomal storage disorder research and assay development.

• Isoliensinine Mitigates Microglial Neuroinflammation via MAP

  2026-07-03

  This study reveals that isoliensinine exerts neuroprotective effects by attenuating LPS-induced neuroinflammation in microglia through modulation of the MAPK/NF-κB pathway. The findings highlight the compound’s impact on oxidative stress and mitochondrial dysfunction, supporting its potential as a therapeutic candidate for Alzheimer’s disease and related neurodegenerative disorders.

• Sorafenib (BAY-43-9006): Multikinase Inhibition in Cancer Mo

  2026-07-02

  Sorafenib (BAY-43-9006) is a potent, orally bioavailable multikinase inhibitor widely used in cancer biology research. It targets Raf-1, B-Raf, VEGFR2, and PDGFRβ, enabling precise antiangiogenic and antiproliferative studies. This article summarizes its mechanism, validated benchmarks, and practical workflow parameters for translational oncology.

• PD0325901 MEK Inhibitor: Advanced Workflows for Cancer & Ste

  2026-07-02

  PD0325901 empowers researchers with highly selective MEK inhibition for dissecting the RAS/RAF/MEK/ERK pathway in oncology and stem cell models. Discover actionable protocols, troubleshooting strategies, and the latest insights on telomerase regulation, all backed by robust comparative evidence.

• RSL3: A Glutathione Peroxidase 4 Inhibitor Transforming Canc

  2026-07-01

  RSL3 enables robust, selective ferroptosis induction for dissecting redox vulnerabilities in cancer, especially in RAS-driven models. This article delivers advanced experimental workflows, troubleshooting insights, and comparative context to help researchers unlock the full potential of this potent glutathione peroxidase 4 inhibitor.

• MLN4924 HCl Salt: Redefining Neddylation Inhibition in Trans

  2026-07-01

  This thought-leadership article offers translational researchers a strategic, mechanistic, and competitive roadmap for leveraging MLN4924 HCl salt in cutting-edge disease modeling. By weaving together recent advances in neddylation pathway research, viral immune evasion, and protein degradation, the article provides actionable experimental guidance, critical evidence, and a forward-looking perspective on the evolving role of NEDD8-activating enzyme inhibitors.

• Intravesical p21 mRNA-LNP: A Tumor Suppressor Therapy for Bl

  2026-06-30

  This study introduces a clinically relevant approach for localized tumor suppressor replacement in bladder cancer using intravesical delivery of p21 mRNA encapsulated in lipid nanoparticles. The innovation lies in restoring p21 expression directly in bladder tissues, significantly suppressing tumor growth and minimizing systemic effects—addressing key therapeutic challenges.

• 2-NBDG as a Strategic Tool for Glucose Metabolism Insight in

  2026-06-30

  This thought-leadership article explores the mechanistic rationale, experimental utility, and translational strategy for using 2-NBDG as a fluorescent glucose uptake tracer in glioblastoma and disease metabolism research. Integrating findings from recent studies, it positions 2-NBDG as a critical bridge for researchers translating metabolic discoveries into actionable interventions, while offering practical guidance on experimental design and interpretation.

• Regorafenib Suppresses Melanoma via RRM2 Downregulation and

  2026-06-29

  This article reviews a recent iScience study elucidating how Regorafenib (BAY 73-4506) inhibits melanoma cell growth, invasion, and metastasis by downregulating RRM2 and modulating ERK/E2F3 signaling. These mechanistic insights refine our understanding of Regorafenib’s action in cancer biology and suggest new avenues for translational research in angiogenesis and tumor progression.

• Erastin and the Immunological Frontier: Ferroptosis for Next

  2026-06-29

  Explore how Erastin, a potent ferroptosis inducer, uniquely bridges oxidative cell death with anti-tumor immunity. This article offers advanced mechanistic insights and practical protocol guidance for translational ferroptosis research.

• Sulfo-NHS-SS-Biotin: Driving Innovation in Cell Surface Prot

  2026-06-28

  This thought-leadership article explores the mechanistic advantages and translational promise of Sulfo-NHS-SS-Biotin, an advanced biotin disulfide N-hydroxysulfosuccinimide ester, for precision cell surface protein workflows. Anchored in recent discoveries around post-translational modifications—such as Fzd4 N-glycosylation in Wnt signaling—the discussion bridges molecular insight, protocol optimization, and strategic guidance for translational scientists. We analyze competitive reagent landscapes, real-world workflow scenarios, and the future impact of cleavable biotinylation strategies, contextualizing APExBIO’s Sulfo-NHS-SS-Biotin as a catalyst for next-generation membrane proteomics.

• Nocodazole as a Microtubule Polymerization Inhibitor: Applie

  2026-06-27

  Nocodazole stands as the gold-standard microtubule polymerization inhibitor, enabling precise manipulation of cell cycle and microtubule dynamics in cancer and virology research. This article dissects real-world protocols, highlights comparative use-cases, and delivers actionable troubleshooting strategies for reproducible results.

• AT13387: Applied Hsp90 Inhibitor Workflows in Cancer Biology

  2026-06-26

  AT13387 stands out as a nanomolar-potency Hsp90 inhibitor enabling precise modulation of oncogenic signaling and apoptosis in cancer biology research. This article bridges innovative findings in programmed cell death with actionable protocols and troubleshooting strategies, empowering scientists to maximize reproducibility and mechanistic clarity.

• HDAC8-Mediated AKT Activation Drives MEK1/2 Inhibitor Resist

  2026-06-26

  This study elucidates how HDAC8 promotes resistance to MEK1/2 inhibition in cancer cells by upregulating PLCB1 and suppressing DESC1, leading to AKT activation. These findings highlight novel molecular targets for overcoming adaptive resistance in MAPK/ERK pathway-targeted therapies.

• DiscoveryProbe™ L1023: Next-Gen Anti-Cancer Library for Path

  2026-06-25

  Explore the DiscoveryProbe™ L1023 Anti-Cancer Compound Library—a curated collection of bioactive molecules enabling advanced pathway interrogation in cancer research. This article uncovers its mechanistic depth and the latest STING pathway insights to empower drug discovery.

15693 records 1/1047 page Next 12345 下5页 Last page